



## **Faculty Disclosures**

This purpose of this information is (1) to identify faculty's relationships and financial interests and (2) to identify educational content that includes off-label uses of products. Conflicts of interest that must be disclosed are (1) any financial relationship with companies that produce, market, or distribute products used on patients and (2) any of these relationships occurred within the last 12 months. The information that is disclosed on this form will be documented within the course syllabus so that an informed audience may formulate their own opinions as to any bias in the information presented.

### **Gale Adcock, MSN, FNP-BC, FAANP, FAAN**

Disclosure/Conflict of Interest: None

Family Conflicts: None

Intent to Discuss Off-Label Use of Medications: None

### **Tracey Anderson, MSN, CNRN, FNP-BC, ACNP-BC**

Disclosure/Conflict of Interest: None

Family Conflicts: None

Intent to Discuss Off-Label Use of Medications: None

### **Steven Atkinson, PA-C, MS**

Disclosure/Conflict of Interest: None

Family Conflicts: None

Intent to Discuss Off-Label Use of Medications: None

### **Nancy R. Berman, MSN, ANP-BC, NCMP, FAANP**

Disclosure/Conflict of Interest: Yes, Consultant: Myovant, Scynexis, Dysis

Family Conflicts: Yes, Abbie, Hologic, Myovant

Intent to Discuss Off-Label Use of Medications: None

**Margaret Bobonich, DNP, FNP-C, DCNP, FAANP**

Disclosure/Conflict of Interest: Consultant/Speakers Bureau: AbbVie, Lilly USA, UCB, Dermavant, Novartis, Biofrontera, Boehringer-Ingelheim; Bristol Myers Squibb; Speaker's Bureau: AbbVie, Lilly USA; Officer/Owner/Employee of Company: Center for Dermatology Nursing Practice

Family Conflicts: None

Intent to Discuss Off-Label Use of Medications: None

**Peter Buch, MD, FACC, AGAF, FACP**

Disclosure/Conflict of Interest: None

Family Conflicts: None

Intent to Discuss Off-Label Use of Medications: None

**Allison E. Burnett, PharmD, PhC, CACP**

Disclosure/Conflict of Interest: None

Family Conflicts: None

Intent to Discuss Off-Label Use of Medications: None

**Amanda Chaney, DNP, APRN, FAANP, AF-AASLD**

Disclosure/Conflict of Interest: None

Family Conflicts: None

Intent to Discuss Off-Label Use of Medications: None

**Victor Czerkasij, MA, MSN, FNP-C**

Disclosure/Conflict of Interest: Yes. Consultant: Arcutis, Incyte Labs; Speaker's Bureau: Abbvie, Sanofi, Genzyme, Janssen

Family Conflicts: None

Intent to Discuss Off-Label Use of Medications: None

**Jana Esden, DNP, APRN, FNP-BC, CNE**

Disclosure/Conflict of Interest: None

Family Conflicts: None

Intent to Discuss Off-Label Use of Medications: None

**Elizabeth Faust, MSN, CRNP, CSWS, CWOCN-AP, DAPWCA**

Disclosure/Conflict of Interest: Consultant & Speaker's Bureau: 3M, Medline, Molnlycke, Urgo Medical, vTail

Family Conflicts: None

Intent to Discuss Off-Label Use of Medications: None

**Margaret A. Fitzgerald, DNP, FNP-BC, NP-C, FAANP, CSP, FAAN, DCC, FNAP**

Disclosure/Conflict of Interest: None

Family Conflicts: None

Intent to Discuss Off-Label Use of Medications: None

**Jason Gleason, MS, FNP-C, USAF Lt Col (RET),**

Disclosure/Conflict of Interest: None

Family Conflicts: None

Intent to Discuss Off-Label Use of Medications: None

**Mikel Gray, PhD, PNP, FNP, CUNP CCCN, FAANP, FAAN**

Disclosure/Conflict of Interest: None

Family Conflicts: None

Intent to Discuss Off-Label Use of Medications: None

**Josh Hamilton, DNP, APRN-BC, CTMH, CNE, FAANP**

Disclosure/Conflict of Interest: Yes, Consultant for Alkermes (new antipsychotic medication); Speaker's Bureau, Myriad Neuroscience for pharmacogenomic testing)

Family Conflicts: None

Intent to Discuss Off-Label Use of Medications: None

**Ellen Karlin, MMSc, RDN, LDN, FADA**

Disclosure/Conflict of Interest: None

Family Conflicts: None

Intent to Discuss Off-Label Use of Medications: None

**Christine Kessler, MN, ANP-BC, CNS, BC-ADM, FAANP**

Disclosure/Conflict of Interest: Yes, Speaker's Bureau: NovoNordisk, Acella, Zealand

Family Conflicts: None

Intent to Discuss Off-Label Use of Medications: Yes, Wegovy; Rybelsus; NP Thyroid, Zegalogue

**Jayant Kumar, MD**

Disclosure/Conflict of Interest: Grant/Research Support: Akebia, Astra Zeneca, Cara

Family Conflicts: None

Intent to Discuss Off-Label Use of Medications: None

**Eric Magana, MD**

Disclosure/Conflict of Interest: None

Family Conflicts: None

Intent to Discuss Off-Label Use of Medications: None

**Mindy D. Mason, MSN, RN, ACNP-BC**

Disclosure/Conflict of Interest: None

Family Conflicts: None

Intent to Discuss Off-Label Use of Medications: None

**Monica Nandwani, DNP, RN, FNP-BC**

Disclosure/Conflict of Interest: Yes, Consultant for Phathom Pharmaceuticals Advisory Board

Family Conflicts: None

Intent to Discuss Off-Label Use of Medications: Yes.

1. Dipenhydramine for Antiemetic.
2. Granisetron for Non-chemo therapy associated nausea & vomiting.
3. Aprepitant for Non-chemo therapy associated nausea & vomiting.
4. Dronabinol for Non-chemo therapy associated nausea & vomiting.
5. Scopolamine for Gastroparesis associated nausea & vomiting.
6. Nortriptyline for Gastroparesis associated nausea, vomiting, pain.
7. Mirtazapine for Appetite stimulation, reduce dyspeptic symptoms.
8. Buspirone for Reduced dyspeptic symptoms..

**Vanessa Pomarico-Denino, EdD, FNP-BC, FAANP**

Disclosure/Conflict of Interest: None

Family Conflicts: None

Intent to Discuss Off-Label Use of Medications: None

**Rick Pope, MPAS, PA-C, DFAAPA, CPAAPA**

Disclosure/Conflict of Interest: None

Family Conflicts: None

Intent to Discuss Off-Label Use of Medications: None

**Amy Siple, FNP**

Disclosure/Conflict of Interest: None

Family Conflicts: None

Intent to Discuss Off-Label Use of Medications: None

**Marianne Vyas, NP, CNRN**

Disclosure/Conflict of Interest: None

Family Conflicts: None

Intent to Discuss Off-Label Use of Medications: None

**Anne Dabrow Woods, DNP, RN, CRNP, ANP-BC, AGACNP-BC, FAAN**

Disclosure/Conflict of Interest: None

Family Conflicts: None

Intent to Discuss Off-Label Use of Medications: Yes, **Session 1:** Baricitinib and JAK inhibitors (Tocilucimab, Baricitinib), Remdesivir, Nirmatrelvir-ritonavir, sotrovimab, bebtelovimab, casirivimab-imdevimab, bamlanivimab-etesevimab— all are emergency use authorization in COVID; Remdesivir is approved for use; **Session 2:** Phenobarbital for alcohol withdrawal syndrome session.

**Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP**

Disclosure/Conflict of Interest: Yes. Consultant: Bayer: CKD; Glaxo: OA/Pain, Moderna, Seqirus, Pfizer, Merck, Sanofi: Vaccines; Idorsia: Insomnia; Shield Therapeutics: IDA; Speakers Bureau: Pfizer, Merck, Sanofi: Vaccines; Biohaven and AbbVie: Migraines

Family Conflicts: None

Intent to Discuss Off-Label Use of Medications: None

**Kim Zuber, PA-C**

Disclosure/Conflict of Interest: None

Family Conflicts: None

Intent to Discuss Off-Label Use of Medications: None